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Abstract. Hutchinson-Gilford progeria (HGPS) is a 
premature aging syndrome associated with LMNA 
mutations. Progeria cells bearing the G608G LMNA 
mutation are characterized by accumulation of a mutated 
lamin A precursor (progerin), nuclear dysmorphism and 
chromatin disorganization. In cultured HGPS fi broblasts, 
we found worsening of the cellular phenotype with pa-
tient age, mainly consisting of increased nuclear-shape 
abnormalities, progerin accumulation and heterochroma-
tin loss. Moreover, transcript distribution was altered in 
HGPS nuclei, as determined by different techniques. In 
the attempt to improve the cellular phenotype, we applied 
treatment with drugs either affecting protein farnesyla-
tion or chromatin arrangement. Our results show that 
the combined treatment with mevinolin and the histone 
deacetylase inhibitor trichostatin A dramatically lowers 
progerin levels, leading to rescue of heterochromatin 
organization and reorganization of transcripts in HGPS 
fi broblasts. These results suggest that morpho-functional 
defects of HGPS nuclei are directly related to progerin 
accumulation and can be rectifi ed by drug treatment.
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Hutchinson-Gilford progeria syndrome (HGPS, OMIM 
176670) is a rare pre-mature aging disorder clinically 
characterized by postnatal growth retardation, midface 
hypoplasia, premature atherosclerosis, absence of subcu-
taneous fat, alopecia and generalized osteodysplasia with 
osteolysis and pathologic fractures [1–3]. Death occurs 
in the teenage usually due to coronary artery disease [2].
HGPS is caused by sporadic mutations in LMNA (OMIM 
150330) coding for alternatively spliced lamins A and C. 
At least fi ve different mutations within the LMNA gene 
have been found in patients with HGPS [3–5]. However, 
most HGPS-described cases harbor an identical C-to-T 
transition at position 1824 of the coding sequence in the 
context of a CpG dinucleotide [2]. This mutation results 
in a silent polymorphism at codon 608 within exon 11 
(G608G), which causes the activation of a cryptic do-
nor-splicing site, resulting in deletion of 150 bp in the 
mRNA [5]. A truncated pre-lamin A isoform is therefore 
translated which has been recently referred to as progerin 
[4, 5]. Progerin lacks 50 amino acids including the en-
doprotease cleavage site present at the C terminus of the 
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wild-type lamin A precursor [2]. Therefore, the HGPS 
pathogenesis is likely to arise from accumulation of the 
mutated 67 kDa isoform of farnesylated pre-lamin A [2]. 
Nuclear envelope-nuclear lamina abnormalities and loss 
of peripheral heterochromatin have been described in 
HGPS fi broblasts [6]. We observed these defects in the 
three cell lines examined in this study and showed that 
they are more represented in cell lines from older patients, 
concomitant with the increased appearance of progerin in 
those cells. In HGPS nuclei, transcript distribution was 
altered, while transcriptional activity was slightly de-
creased, despite the massive chromatin decondensation. 
In an attempt to destabilize the farnesylated protein, we 
treated HGPS cells with a farnesyl-transferase inhibitor 
(mevinolin). We observed a slight decrease in the amount 
of progerin and rescue of heterochromatin organization 
in a low percentage of mevinolin-treated cells. In a sec-
ond step, we attempted to restore heterochromatin areas 
in HGPS nuclei using drugs known to modify chromatin 
organization. Unexpectedly, rescue of heterochromatin 
organization and transcript distribution was obtained in a 
high percentage of HGPS fi broblasts receiving combined 
treatment with mevinolin and trichostatin A. This treat-
ment also dramatically lowered the progerin level. 
Materials and methods
Cell cultures. Skin fi broblast cultures from three HGPS 
patients carrying a G608G lamin A/C mutation were 
obtained from the Progeria Research Foundation, while 
control cultures were obtained in our laboratory from 
skin biopsies of unaffected controls (age 2 to 50) follow-
ing written consent. Fibroblast cultures were established 
and cultured in Dulbecco’s modifi ed Eagle’s medium 
supplemented with 10% fetal calf serum (FCS) and an-
tibiotics (penicillin, 50 units/ml; streptomycin, 50 mg/ml; 
amphotericin B, 250 µg/ml).
The three HGPS cell lines were: HGADFN001 (age 9 
years, passage 13), HGADFN003 (age 2 years, passage 
13), HGADFN127 (age 3 years, passage 7). The experi-
ments were performed at these passage numbers, except 
when stated otherwise.
Drug treatments. To induce defarnesylation of progerin, 
25 µM mevinolin (Sigma) was added to the culture medi-
um for 18 h. The following chromatin-modifying agents 
were used: (i) 5-azadeoxycytidine (Sigma), (ii) anacardic 
acid (Sigma), (iii) trichostatin A (TSA) (Sigma). 5-Aza-
deoxycytidine was applied to cultured fi broblasts for 18 h 
following mevinolin treatment. This drug inhibits DNA 
methylation and, at the dosage here employed (10 µM 
for 18 h), elicits constitutive heterochromatin deconden-
sation [7]. The inhibitor of histone acetyl transferases, 
anacardic acid, was applied to cultured fi broblasts for 
18 h at 9 µM. The histone deacetylase (HDAC) inhibitor 
TSA (Sigma) [8] was applied to cell cultures as follows. 
Samples were pretreated or not with mevinolin for 18 h, 
thereafter culture medium was replaced and 1.5 µM TSA 
was added for 24 h [8]. 
Antibodies. Antibodies employed for Western blot (WB) 
analysis or immunofl uorescence (IF) labeling were: anti-
lamin A/C monoclonal (Novocastra Laboratories), diluted 
1:50 for IF analysis; anti-lamin A/C goat polyclonal (Santa 
Cruz, SC-6215), diluted 1:100 for IF analysis and 1:100 for 
WB analysis; anti-pre-lamin A goat polyclonal (Santa Cruz, 
SC-6214) [9] diluted 1:100 for WB analysis; anti-emerin 
mouse monoclonal (Novocastra Laboratories) diluted 1:50 
for IF analysis and 1:100 for WB analysis; anti-trimethyl-
ated-H3 histone (lysine 9) (tri-H3K9), mono-methylated 
(lysine 9) H3 histone (mono-H3K9) and dimethylated- H3 
histone (lysine 9) (di-H3K9) (Abcam) diluted 1:30 for IF 
analysis; anti-BrdU monoclonal antibody (BD-Bioscienc-
es) diluted 1:1000 for IF analysis; anti-lamin A 2H10 
monoclonal antibody [10] diluted 1:400 for IF analysis.
In situ transcription assay. Living fi broblasts were 
treated according to published protocols [10]. Briefl y, 
cells were permeabilized in a buffer containing 20 mM 
Tris-HCl (pH 7.4), 5 mM MgCl2, 0.5 mM EGTA, 25% 
glycerol, 10 µg/ml digitonin, 1 mM PMSF, RNasin (20 U/
ml). The transcription assay was performed for 5 min in 
a buffer containing 50 mM Tris-HCl, pH 7.4, 100 mM 
KCl, 10 mM MgCl2, 0.5 mM EGTA, 25% glycerol, 2 mM 
ATP, 0.5 mM CTP, 0.5 mM GTP, 0.5 mM BrUTP, 1 mM 
PMSF and RNasin (20 U/ml). Alpha-amanitin (10 µg/ml) 
(Sigma) was added to the transcription buffer to obtain 
negative controls (not shown). Cells were washed in PBS 
and fi xed in 2% paraformaldehyde at room temperature. 
Incorporated nucleotides were revealed by immunofl uo-
rescence labeling with anti-BrdU antibody.
Western blot. Western blot analysis of cellular lysates 
from human fi broblasts was done as follows. Cells were 
lysed in buffer containing 10 mM Tris-HCl, pH 7.4, 1% 
Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate, 
1 mM NaVO3, 150 M NaCl, 1 mM EDTA, 1 mM PMSF, 1 
µM aprotinin, leupeptin, pepstatin. Proteins were loaded 
in Laemmli sample buffer and subjected to SDS-PAGE 
followed by immunochemical reactions. Immunoblotted 
bands were detected by enhanced chemiluminescence 
(Amersham).
Immunofl uorescence. Human fi broblasts grown on cov-
erslips were fi xed in paraformaldheyde 4% in PBS at 4 °C 
and post-fi xed in methanol at –20 °C for 7 min. Samples 
were incubated with PBS containing 4% BSA to saturate 
non-specifi c binding. Incubation with primary antibodies 
was performed overnight at 4 °C, while secondary anti-
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Figure 1. Nuclear defects in 
HGPS fi broblasts. (A) West-
ern blot analysis of lamins 
in HGPS fi broblasts. Lamin 
A and C were expressed at 
normal levels in the cell lines 
HGADFN003 (passage 13) 
and HGADFN127 (passage 
7), while both lamin A and 
C levels were decreased in 
the cell line HGADFN001 
(passage 13). Progerin (67 
kDa) was detected in all 
examined cellular lysates, 
with an increased proportion 
relative to mature lamin A 
in the older patient cell line 
HGADFN001. The emerin 
level was not altered in HGPS 
cells. Molecular-weight 
markers are reported in kDa. 
The age of each patient is 
indicated (y, years), the 
number of cell passages is 
indicated in the lower row 
(p, passages). (B) One control 
cell line and three HGPS cell 
lines (HGADFN003, HGAD-
FN127 and HGADFN001; 
see Materials and methods 
for details) were examined by 
IF analysis using anti-lamin 
A/C (green) and anti-emerin 
antibodies (red). The nuclear 
shape was altered in HGPS 
fi broblasts and the nuclear 
envelope invaginations are 
evident. Emerin mostly co-
localized with lamin A/C. 
Nuclear shape abnormalities 
increased in the older cell 
line. (C) Ultrastructural 
analysis of control and HGPS 
nuclei (HGADFN003, 
HGADFN127 and HGAD-
FN001; see Materials and 
methods for details). Nuclear 
invaginations are evident in 
50% of examined nuclei from 
HGADFN127 cells and their 
frequency increased in HGADFN003 and HGADADFN001 cells. Heterochromatin loss was observed in all HGPS cell lines and heterochro-
matin areas were completely absent from HGADFN0001 nuclei. Nuclear invaginations including the outer nuclear membrane (arrowheads) 
or selectively involving the inner nuclear membrane and the lamina (including the perinuclear cisterna, arrows) are shown. (D) Quantitation 
of misshapen nuclei shown in B. Nuclei showing at least fi ve invaginations were considered nuclei with invaginations (left columns). Nuclei 
showing an increase in the major diameter of at least 20% of control nuclei were considered enlarged nuclei (right columns). One thousand 
nuclei were scored per cell line (see legend for details). Triplicate staining experiments (lamin A/C-emerin staining) were examined. Mean 
values including standard errors of the mean were calculated and reported as percentage of counted nuclei.
bodies were applied for 1 h at room temperature. Slides 
were mounted with an anti-fade reagent in glycerol and 
observed with a Nikon E 600 fl uorescence microscope 
equipped with a digital camera. Pictures were elaborated 
with Photoshop-6 software.
Electron microscopy. Cell pellets from control and 
HGPS fi broblasts (subjected or not to drug treatment) 
were fi xed with 2.5% glutaraldehyde-0.1 M phosphate 
buffer pH 7.3 for 1 h at room temperature. After post-fi x-
ation with 1% osmium tetroxide (OsO4) in veronal buffer 
for 1 h, pellets were dehydrated in an ethanol series, infi l-
trated with propylene oxide and embedded in Epon resin. 
Ultrathin sections (60 nm thick) were stained with uranyl 
acetate and lead citrate (10 min each) and were observed 
at 0° tilt angle with a Philips EM 400 transmission elec-
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tron microscope, operated at 100 kV. At least 200 nuclei 
per sample were observed.
Regressive EDTA staining was carried out according to 
the procedure of Bernhard [11]. Briefl y, ultrathin sections 
of Epon-embedded control or HGPS fi broblasts (fi xed 
with 2.5% glutaraldehyde in phosphate buffer pH 7.3, 
avoiding OsO4 post-fi xation) were fl oated for 10 min on 
5% aqueous uranyl acetate at room temperature, washed 
with distilled water and treated with 0.2 M EDTA for 
60 min. Sections were washed with distilled water and 
contrasted for 10 min with standard lead citrate at room 
temperature.
Results
Progerin accumulation in HGPS fi broblasts correlates 
with nuclear defects. Progerin was detected in the three 
examined cell lines by Western blot analysis (fi g. 1A). An 
increased proportion of progerin relative to mature lamin 
A was determined in the cell line HGADFN001 from the 
older patient (fi g. 1A). The lamin A/C level was reduced 
in HGADFN001 fi broblasts (fi g. 1A). Emerin expression 
was not affected in HGPS cells (fi g. 1A). 
Nuclear shape was dramatically altered in HGPS fi brob-
lasts, with enlarged nuclei characterized by invagina-
tions and blebs (fi g. 1B). Double-immunofl uorescence 
labeling of HGPS fi broblasts was performed using anti-
lamin A/C and anti-emerin antibodies. Lamin A/C and 
emerin mostly co-localized in progeria nuclei (fi g. 1B). 
Worsening of nuclear envelope defects with patient age 
was evident (compare HGADFN003 and HGADFN001 
nuclei; fi g. 1B).
Electron microscopy analysis of HGPS nuclei confi rmed 
the worsening of nuclear defects with patient age (fi g. 
1C). Focal loss of peripheral heterochromatin was ob-
served in most nuclei, while heterochromatin areas be-
came almost undetectable in the older cell line (fi g. 1C). 
Nuclear envelope invaginations were observed (fi g. 1C). 
In some instances, nuclear invaginations also contained 
the outer nuclear membrane (fi g. 1C; arrowheads), but 
more often were devoid of the outer nuclear membrane 
and included the perinuclear cisterna (fi g. 1C; arrows). 
Methylation of H3 histone is altered in HGPS nuclei. 
The methylation pattern of H3 histone was investigated 
in HGPS cells. Figure 2 shows immunofl uorescence 
labeling of mono-, di- and tri-H3K9 in HGADFN127 
fi broblasts. Mono-H3K9 staining was reduced in HGPS 
nuclei and was moderately detectable in 10–20% of 
Figure 2. Immunofl uores-
cence labeling of methylated 
H3 histone species in control 
and HGPS fi broblasts. H3K9 
labeling was performed by 
specifi c antibodies and re-
vealed by FITC-conjugated 
secondary antibody (green); 
lamin A/C was labeled by 
polyclonal antibody and re-
vealed by Cy-3-conjugated 
secondary antibody (red); 
DNA was counterstained 
with DAPI; mono- H3K9 la-
beling (A); di- H3K9 label-
ing (B); tri-H3K9 labeling 
(C). A representative experi-
ment performed in HGAD-
FN127 fi broblasts is shown 
in this picture. Quantitation 
of H3K9 staining shown 
in each panel is reported 
on the right. Bars show the 
mean percentage of nuclei 
with reduced fl uorescence 
intensity. Nuclei with re-
duced fl uorescence intensity 
were considered the nuclei 
with less than 50% of the 
mean fl uorescence intensity 
measured in control nuclei 
(Lucia Image Version 4.61 
software was used to mea-
sure fl uorescence intensity 
per area). Mean values of triplicate counting performed in each patient cell line (see legend for details) including standard errors of the 
mean were calculated.
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nuclei (fi g. 2A). The labeling pattern of di-H3K9 was 
comparable to controls (fi g. 2B), while a dramatic altera-
tion of tri-H3K9 was observed in HGPS cells. Twenty 
percent of HGADFN127 nuclei were negative for tri-
H3K9 staining (fi g. 2C). Even more striking alterations 
of labeling patterns were observed in the other HGPS 
cell lines (fi g. 2C, graph). These results show that both 
facultative heterochromatin methylation (detected by 
mono-H3K9 labeling) and constitutive heterochromatin 
methylation (revealed by tri-H3K9 staining) [12] are 
altered in HGPS.
Progerin accumulation is reduced by mevinolin 
treatment. In the attempt to destabilize progerin, we 
used mevinolin to obtain defarnesylation. Figure 3A 
shows the WB analysis of progerin in HGPS fi broblasts 
subjected to mevinolin treatment. Control fi broblasts 
were also treated with the farnesyltransferase inhibitor 
and subjected to Western blot analysis using anti-lamin 
A/C antibody (fi g. 3) and anti-pre-lamin A antibody (not 
shown). Beside the expected increase in wild-type pre-
Figure 3. WB analysis of 
 lamins in drug-treated HGPS 
fi broblasts. Control and 
HGPS fi broblasts were 
subjected to drug treatment, 
lysed and protein separation 
was obtained by SDS-PAGE. 
An immunoblot was per-
formed using anti-lamin A/C 
or anti-emerin antibodies. (A) 
Untreated control fi broblasts 
show an almost undetectable 
amount of pre-lamin A (lane 
1). Untreated HGPS fi brob-
lasts show a low amount of 
wild-type pre-lamin A and 
a high amount of progerin 
(lane 3). Increased pre-lamin 
A levels were observed after 
mevinolin addition in all ex-
amined cell lines (lanes 2 and 
4). The amount of progerin 
was reduced in mevinolin-
treated HGPS cells (lane 4). 
(B) Further treatment with 
TSA led to a slight reduc-
tion in wild-type pre-lamin 
A levels (lanes 5, 8), while 
the progerin level was strik-
ingly lowered (lane 8). TSA 
treatment (in the absence of 
mevinolin) slightly increased 
the lamin A/C level both in control (lane 6) and HGPS cells (lane 9), but minimally affected the progerin level (lane 9). The Wild-type pre-
lamin A was reduced by addition of 5-azadeoxycytidine (5-AC) to mevinolin-treated control (lane 7) and HGPS cells (lane 10). The amount 
of progerin was not affected by 5-AC (lane 10). The lamin A/C level was minimally affected by 5-AC (lane 7 and 10). Emerin was not altered 
by drug treatments in control or HGPS cell lines. Actin bands are labeled as a loading control. A representative experiment is shown of three 
different experiments performed in each control and HGPS cell line. (C) Densitometric analysis of pre-lamin A and progerin immunoblot-
ted bands shown in A and B. Pre-lamin A values are reported as the percentage of pre-lamin A amount detected in mevinolin-treated cells; 
progerin values are reported as the percentage of progerin amount detected in untreated HGPS cells. Values are the mean ± standard error of 
the mean of three independent experiments performed in HGADFN001 cells.
lamin A caused by mevinolin in all the examined cell 
lines, a decrease in the amount of progerin was observed 
in HGPS lysates (fi g. 3A). The lamin A level was slightly 
reduced by mevinolin treatment, while amounts of lamin 
C and emerin were not affected (fi g. 3A). 
Progerin accumulation is abolished by mevinolin/TSA 
treatment. In the attempt to investigate heterochromatin 
dynamics in HGPS nuclei, we treated HGPS fi broblasts 
with a set of drugs capable of interfering with chromatin 
organization. The effect of each treatment on progerin 
accumulation was evaluated by WB analysis (fi g. 3B). 
Treatment of progeria fi broblasts with 5-azadeoxycytidine 
slightly increased the amount of progerin (not shown). 
TSA treatment of HGPS fi broblasts slightly affected the 
progerin level (fi g. 3B, lane 9). Addition of each chroma-
tin-modifying drug to mevinolin-treated cells elicited the 
following effects. 5-Azadeoxycytidine addition lowered 
wild-type pre-lamin A levels both in control and HGPS 
cells (fi g. 3B, lane 7 and 10). Dramatic lowering of the 
progerin level was observed in HGPS cells sequen-
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ardic acid elicited effects on progerin and mature lamin 
A expression, which, however, were not consistent and 
require further investigation (not shown). We performed a 
statistical evaluation of wild-type pre-lamin A and proger-
tially treated with mevinolin and TSA (fi g. 3B, lane 8). 
A moderate reduction in wild-type pre-lamin A was also 
observed in these cells, while lamin A and C levels were 
slightly affected by TSA addition (fi g. 3B, lane 8). Anac-
Figure 4. Heterochromatin 
organization in mevinolin/
TSA-treated HGPS fi broblasts. 
(A–D) Experiments are repre-
sentative of three independent 
analyses performed in each cell 
line, and the pictures were ob-
tained by transmission electron 
microscopy. (A) Heterochro-
matin areas are evident at the 
nuclear periphery of untreated 
control nuclei, except at the 
nuclear pores (*). In untreated 
HGADFN001 nuclei, periph-
eral heterochromatin is absent. 
(B) Mevinolin treatment elic-
ited formation of heterochro-
matin areas both in control and 
HGPS cells. The percentage of 
nuclei showing heterochroma-
tin areas was increased by 5% 
in HGADFN001 nuclei. (C) 
TSA treatment did not signifi -
cantly change the number of 
nuclei with heterochromatin 
areas either in control or in 
HGPS cells. (D) Mevinolin 
plus TSA treatment slightly 
affected heterochromatin 
organization in control fi brob-
lasts, while it raised to 40% the 
percentage of HGADFN001 
nuclei showing heterochro-
matin areas. (E) Double-IF 
staining of tri-H3K9 and lamin 
A/C in HGADFN001 fi brob-
last nuclei. Anti-tri-H3K9 
antibody was revealed by 
FITC-conjugated secondary 
antibody (green); anti-lamin 
A/C antibody was revealed by 
Cy3-conjugated secondary an-
tibody (red). Tri-H3K9 labeled 
discrete foci in control nuclei 
(control), while labeling was 
lost in 36% of HGPS nuclei 
(HGPS). Mevinolin treatment 
(mevinolin) did not affect the 
number of tri-H3K9-positive 
control cells, while slightly 
increasing the number of tri-
H3K9-positive HGPS cells. 
TSA treatment (TSA) affected 
the distribution of tri-H3K9 
foci in control cells, while it 
was not effective in HGPS 
cells. In HGPS nuclei, com-
plete recovery of tri-H3K9 
labeling was obtained after 
mevinolin + TSA treatment (mevinolin/TSA). (F) Quantitation of the electron microscopy analysis shown in panels A–D. The percentage of nuclei 
showing at least four heterochromatin areas was reported for control and HGADFN001 fi broblasts. (G) Quantitation of tri-H3K9 positive nuclei in 
HGADFN001 fi broblasts before and after each drug treatment (shown in E). Mean values of triplicate experiments including standard errors of the 
mean were calculated. One thousand nuclei per sample were counted. 
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in densitometric values referred to immunoblotted bands 
(fi g. 3C). A signifi cant decrease in progerin accumulation 
is clearly obtained by mevinolin/TSA administration (fi g. 
3C). The overall evaluation of graphs shows that each 
drug treatment elicited very different effects on wild-type 
compared to mutated lamin A precursor (fi g. 3C). 
Heterochromatin organization in HGPS nuclei is 
improved by mevinolin/TSA treatment. By ultrastruc-
tural analysis, heterochromatin areas were not detected 
in untreated HGADFN001 fi broblasts (fi g. 4A), while 
they were observed at the nuclear periphery in 5% of 
mevinolin-treated HGADFN001 fi broblasts (fi g. 4B). 
However, mevinolin treatment of HGPS fi broblasts ap-
parently failed to improve nuclear shape abnormalities 
(not shown). TSA alone did not cause detectable changes 
in chromatin organization in control or in HGPS cells 
(fi g. 4C). In all the examined HGPS cell lines, adminis-
tration of mevinolin plus TSA elicited reorganization of 
peripheral heterochromatin (fi g. 4D). Nuclear shape was 
also improved after the combined treatment with mevino-
lin and TSA (fi g. 4D). 
To support the reported fi ndings, we checked the distri-
bution of tri-H3K9 before and after mevinolin/TSA treat-
ment. Tri-H3K9 stained discrete sites in control nuclei, 
but labeling was not detected in most HGPS nuclei (fi g. 
2C, 4E). Tri-H3K9 staining was increased in a minor, not 
statistically signifi cant percentage of mevinolin-treated 
HGPS cells (fi g. 4E). Histone staining was restored by 
mevinolin/TSA treatment of each cell line (fi g. 4E). 
Statistical analysis of the experiments shown in fi gure 4 
A–D is reported in fi gure 4F. The percentage of nuclei 
showing at least four heterochromatin areas rose to 40% 
in HGADFN001 cells after mevinolin/TSA treatment 
(fi g. 4F). Figure 4G shows the statistical analysis of 
the experiments shown in Figure 4E. The percentage of 
HGPS nuclei showing tri-H3K9 staining is increased to 
almost 100% by mevinolin/TSA treatment (fi g. 4G).
Ribonucleoprotein levels are reduced in HGPS cells 
and restored by mevinolin/TSA treatment. We sought 
to determine if the increased availability of dispersed 
chromatin could affect the transcriptional activity of 
HGPS nuclei. In particular, we wished to determine if 
dispersed chromatin areas observed by electron micro-
scopy corresponded to domains of increased transcript 
accumulation. An altered distribution of mRNA tran-
scripts was revealed by an in situ transcription assay. 
Control nuclei showed a uniform staining of BrU all 
over the nucleus (fi g. 5A). The amount of incorporated 
BrU was reduced in enlarged HGPS nuclei showing 
major nuclear lamina defects and BrU-containing tran-
scripts were distributed in the nucleus with a non-uni-
form pattern (fi g. 5A). After treatment with mevinolin 
and TSA, BrU incorporation was comparable to con-
trols in most HGPS nuclei, including some enlarged 
nuclei (fi g. 5A). Uniform BrU staining was observed 
in HGPS nuclei after mevinolin/TSA treatment (fi g. 
5A). Reverse EDTA staining of control nuclei allowed 
us to identify ribonucleoproteins distributed to discrete 
clusters throughout the nuclei except at the nuclear 
periphery, where bleached chromatin was evident (fi g. 
5B, control). In mevinolin/TSA-treated control nuclei, a 
uniform distribution of transcripts all over the nucleus 
was observed (fi g. 5B, mevinolin/TSA control). Ribo-
nucleoprotein staining was dramatically reduced in 36% 
of HGPS nuclei and a faint gray staining was observed 
throughout the nucleus, including the nuclear periphery 
(fi g. 5B, untreated HGPS). Bleached chromatin areas 
at the nuclear lamina were absent, while an irregular 
thickening of the lamina was revealed (fi g. 5B, arrows). 
Mevinolin/TSA treatment of HGPS cells restored the 
ribonucleoprotein distribution (fi g. 5B, mevinolin/TSA 
HGPS) and improved nuclear lamina organization lead-
ing to rescue of heterochromatin areas (arrowheads). An 
altered distribution of intranuclear lamin A associated 
with splicing factor compartments was observed in all 
HGPS cell lines (fi g. 5C). Mevinolin/TSA treatment re-
stored the intranuclear lamin A labeling pattern in HGPS 
nuclei (fi g. 5C).
Discussion
The results reported in this study show that progerin ac-
cumulation, nuclear envelope alterations and chromatin 
disorganization in HGPS correlate with patient age and 
are associated with defects of transcript accumulation 
and distribution. We demonstrate that both nuclear-shape 
abnormalities and heterochromatin organization may be 
rescued by treating HGPS fi broblasts with a farnesyl-
transferase inhibitor, followed by a chromatin-modify-
ing drug. Reversal of the nuclear defects is related to 
lowering of the progerin level in drug-treated samples 
and also elicits recovery of the ribonucleoprotein stain-
ing pattern.
Worsening of the HGPS cellular phenotype with pa-
tient age is clearly shown by the formation of nuclear 
introfl ections, blebs and enlargement of nuclei, as well 
as by progressive loss of peripheral heterochromatin. 
These aspects are related to the increased proportion of 
progerin relative to mature lamin A found in HGPS cells 
from older patients. On the other hand, a combination of 
factors is likely to cause the progressive worsening of nu-
clear defects observed in HGPS. In our hands, fi broblasts 
from the 3-year-old patient are in fact less affected than 
those from the 2-year-old patient (which are at a higher 
passage number). We suggest that both passage number 
[6] and patient age contribute to worsening of the cellular 
phenotype. However, we cannot rule out the possibility 
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of an involvement of the genetic background in the dif-
ferent severity of the cellular defects observed in HGPS 
cells from different patients. 
Although we observe a slight reduction in mature lamin 
A in the older patient cell line, literature data [13, 14] and 
our results obtained in the present study strongly suggest 
that the severe defects of HGPS cells are due to progerin 
accumulation. Here we show that removal of progerin 
from HGPS fi broblasts can be obtained by drug treat-
ment and is associated with an important improvement in 
the cellular phenotype. As expected, wild-type pre-lamin 
A also accumulates in mevinolin/TSA-treated cells. This 
could be expected to elicit a toxic effect, as wild-type pre-
lamin A has been shown to be toxic for transgenic mice 
[9, 13, 15] and humans [16–18]. However, it is worth 
noting that, after mevinolin treatment, a non-farnesylated 
lamin A precursor accumulates. This protein elicits very 
different effects on heterochromatin organization and 
on the whole cellular phenotype in comparison to far-
nesylated pre-lamin A [G. Lattanzi et al., unpublished 
results], as suggested by Fong et al. [13]. 
Results obtained by drug treatments further confi rm that 
the amount of progerin accumulated in each HGPS cell 
culture directly determines the severity of the cellular 
phenotype. In fact, a slight reduction of progerin level by 
mevinolin corresponds to recovery of heterochromatin 
organization in a minor (though signifi cant) proportion of 
cells. On the other hand, recovery of the heterochromatin 
Figure 5. Transcript distribu-
tion was altered in HGPS 
nuclei. (A) In situ transcrip-
tion assay showing uniform 
BrU staining in control nuclei 
(91% out of 200 counted 
nuclei) and reduced tran-
scriptional activity and non-
uniform BrU distribution in 
enlarged HGADF001 nuclei 
(41% out of 200 counted 
nuclei). Uniform BrU stain-
ing was observed in HGPS 
nuclei after mevinolin/TSA 
treatment (83% out of 
200 counted nuclei) (right 
column). RNA transcripts 
incorporating BrU were la-
beled by anti-BrU antibody 
and revealed by Cy-3-con-
jugated secondary antibody 
(red). The nuclear lamina 
was labeled by anti-lamin 
A/C antibody and revealed by 
FITC-conjugated secondary 
antibody (green). The merged 
images (merge) underscore 
the different BrU distribution 
in control and HGPS nuclei. 
Images were obtained by 
fl uorescence microscopy. (B) 
EDTA-reverse staining of a 
control and an HGADFN001 
nucleus. In the control nucle-
us, clusters of electron-dense 
ribonucleoproteins were ob-
served at the nuclear interior, 
while peripheral bleached 
heterochromatin was detected as unstained areas (arrowhead) (96% out of 200 observed nuclei); EDTA staining was observed throughout 
the nucleus in mevinolin/TSA-treated controls (74% out of 200 observed nuclei). In untreated HGPS nuclei, a diffuse gray staining was ob-
served and electron-dense ribonucleoproteins were reduced (36% out of 200 observed nuclei) (the irregular thickness of the nuclear lamina 
was indicated by arrows); in mevinolin/TSA-treated HGPS nuclei ribonucleoprotein staining was restored and bleached heterochromatin 
areas were detected at the nuclear periphery (arrowheads) (87% out of 200 observed nuclei). Different patterns of ribonucleoprotein stain-
ing were seen within the rectangle areas; images were taken by transmission electron microscopy. (C) The labeling pattern of intranuclear 
lamin A labeled by the 2H10 antibody corresponded to a speckled distribution (control) (95% out of 200 observed nuclei); mevinolin/TSA 
treatment did not affect 2H10 labeling in the majority of control nuclei (76% out of 200 observed nuclei); lamin A 2H10 stained in irregu-
larly distributed foci at the nuclear interior of HGADFN001 cells (HGPS, untreated) (53% out of 200 observed nuclei); a staining pattern 
comparable to control nuclei was obtained by treating HGPS cells with mevinolin/ TSA (HGPS, mevinolin/TSA) (81% out of 200 observed 
nuclei). A representative experiment was shown of triplicate experiments performed for each HGPS cell line.
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arrangement along with improvement of nuclear-shape 
abnormalities is observed in a high percentage of HGPS 
cells after progerin removal. It should be noted that 
TSA was effective in reducing the progerin level only in 
mevinolin-pretreated cells, indicating that defarnesyla-
tion of the mutated protein allows destabilization. This 
aspect is a crucial point in the understanding of HGPS 
pathogenesis. Recently published papers [19–22] show 
that farnesyl-transferase inhibitors cause relocalization 
of progerin at the nuclear interior. This effect appears 
to improve nuclear shape [19–22]. These and our results 
suggest that defarnesylation of progerin represents the 
fi rst step toward an improvement of the cellular pheno-
type. Release of the mutated protein from one nuclear 
region to another appears to be the fi rst effect of prog-
erin defarnesylation [19–22]. The subsequent reduction 
in progerin level we obtained by TSA addition more 
likely affects newly established protein interactions (see 
below). The major role of progerin in the HGPS patho-
genetic mechanism is also supported by other recently 
published data [14] showing that recovery of the nuclear 
phenotype is obtained in HGPS fi broblasts by correction 
of the aberrant LMNA splicing leading to reduced prog-
erin transcription [14]. 
Increased HDAC activity and increased levels of HDACs 
bound to unphosphorylated pRB (the protein product of 
the retinoblastoma gene) have been found in senescent 
cells [8]. TSA, which inhibits HDAC activity, has been 
suggested to reverse the cellular phenotype from senes-
cent to proliferating by activating the cyclin E promoter 
[8]. We cannot completely rule out the possibility that 
pre-lamin A (and/or progerin) might be involved in the 
protein complex including pRB, HDACs and the E2F 
transcription factor to affect the stability of the protein 
complex itself. Lamin A does in fact interact with pRB 
and E2F in the protein complex anchored by the lamina-
associated polypeptide 2 alpha (LAP2a) [23]. How-
ever, the reason why TSA does not elicit the expected 
decondensation effect on chromatin in HGPS nuclei is 
not obvious. We hypothesize either an altered distribution 
of chromatin-regulating factors including HDACs, or a 
mislocalization of mutated lamin A precursor affecting 
the composition of chromatin-regulating complexes in 
HGPS. Both these situations might explain the unex-
pected effects produced by inhibition of HDACs.
Our results suggest that mevinolin/TSA treatment leads 
to progerin degradation rather than to impairment of 
progerin synthesis. The fi nding that mevinolin /TSA 
treatment reduces the progerin level, while wild-type 
pre-lamin A is not or only minimally affected suggests 
that there is not a down-regulation of pre-lamin A ex-
pression. Moreover, the amount of progerin is dramati-
cally reduced only in cells pretreated with mevinolin. 
This strongly suggests that defarnesylation of progerin 
is necessary to obtain protein loss. It appears unlikely 
that TSA might down-regulate progerin synthesis only 
after mevinolin treatment. A destabilization mechanism 
appears more acceptable. Our preliminary results show 
that defarnesylation of pre-lamin A allows formation of 
protein-protein interactions (G. Lattanzi et al., unpub-
lished results). We propose that the reduction in progerin 
level obtained by TSA addition more likely affects newly 
established protein interactions. 
Massive chromatin decondensation observed in HGPS 
fi broblasts does not correspond to increased transcrip-
tional activity. Instead, regressive staining of nuclei 
allowed us to show that the pool of ribonucleoproteins 
is reduced in HGPS nuclei. In agreement with this fi nd-
ing, the distribution of incorporated BrU was altered 
in enlarged HGPS nuclei, as determined by an in situ 
transcription assay. The reduced ribonucleoprotein stain-
ing that characterizes progeria nuclei is suggestive of an 
aberrant mechanism affecting transcript accumulation, 
possibly due to the disproportion between open chro-
matin areas and the available pool of the transcriptional 
machinery. This hypothesis is in agreement with the ob-
servation that intranuclear lamin A associated with splic-
ing factor compartments is mislocalized in HGPS cells. 
Both the ribonucleoprotein staining pattern and the rate 
of BrU incorporation, as well as the localization of intra-
nuclear lamin A sites were improved by mevinolin/TSA 
treatment of HGPS cells, indicating that reorganization 
of heterochromatin domains corresponds to functional 
recovery.
The reported data argue for a major role of progerin in 
chromatin organization and dynamics. Our results also 
suggest a role for wild-type pre-lamin A in heterochro-
matin dynamics. For example, we observed a dramatic 
decrease in pre-lamin A accumulation in cells treated 
with the chromatin demethylating agent 5-azadeoxyciti-
dine. Interestingly, a role for pre-lamin A in the organiza-
tion of chromatin domains has been suggested [24, 25] 
and a DNA-binding domain in the lamin A carboxy-ter-
minus sequence has been determined [26]. Moreover, 
heterochromatin defects feature in all the laminopathies 
described so far [6, 10, 27–30]. Evidence of pre-lamin A 
involvement in chromatin dynamics will be presented in 
another study [G. Lattanzi et al., unpublished results].
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